Send Me an Angel: More VC Alternatives on the Rise

November 28, 2011 – 10:30 am | By Trista Morrison | No comments yet

It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately.

I have no quantitative data to back this up. But it’s a feeling I had earlier this year, too, as we reported on some big non-VC start-up rounds, like Ascletis Inc.’s $100 million raised largely from high net worth investors in China, and Acetylon Pharmaceuticals Inc.’s $27 million Series B round raised in $1 million chunks from private individuals. We even made this subject the topic of BioWorld’s BIO 2011 panel.

The trend appears to be continuing. Avaxia Biologics Inc. just raised $2.2 million in Series A financing from angels. Karyopharm Therapeutics Inc. closed a $10 million Series A2 round led by Chione Ltd., a Greek investment vehicle for a high net worth individual. Quanticel Pharmaceuticals Inc. raised $45 million through a unique deal with Celgene Corp. and Versant Ventures. And last month, Russia’s state-owned investment firm Rusnano made some big bets on Selecta Biosciences Inc. and Bind Biosciences Inc.

Non-VC deals are still the minority, but they seem to be ever so slightly more common than in the past. I’m guessing this is a trend born of necessity – with so many VCs pulling back (Prospect Ventures, Scale Venture Partners, etc.), start-ups might be forced to seek alternatives more often than in the past.

But even so, the fact that alternatives exist is encouraging. I’m a self-professed optimist on biotech, but I’m even further encouraged by the bills moving through Congress that could boost small company fundraising options. For start-ups in particular, H.R. 2930 could be good news, as it would let private companies raise up to $2 million through crowd funding, essentially opening the private markets to non-accredited investors. For all the details, don’t miss this week’s BioWorld Insight.

Share

Post a Comment

You must be logged in to post a comment.

Register To Comment

Please register to comment on the BioWorld Perspectives blog. An email will be sent to you with your login and password information. Please store this for future use. Subscribers to BioWorld publications must also register.